Cargando…
Gender Bias in U.S. Pediatric Growth Hormone Treatment
Growth hormone (GH) treatment of idiopathic short stature (ISS), defined as height <−2.25 standard deviations (SD), is approved by U.S. FDA. This study determined the gender-specific prevalence of height <−2.25 SD in a pediatric primary care population, and compared it to demographics of U.S....
Autores principales: | Grimberg, Adda, Huerta-Saenz, Lina, Grundmeier, Robert, Ramos, Mark Jason, Pati, Susmita, Cucchiara, Andrew J., Stallings, Virginia A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650610/ https://www.ncbi.nlm.nih.gov/pubmed/26057697 http://dx.doi.org/10.1038/srep11099 |
Ejemplares similares
-
SUN-249 Growth Hormone Utilization By US Youth: Trends as Insurance Pushes Back after FDA-Approved Expansion
por: Grimberg, Adda, et al.
Publicado: (2019) -
US Growth Hormone Use in the Idiopathic Short Stature Era: Trends in Insurer Payments and Patient Financial Burden
por: Grimberg, Adda, et al.
Publicado: (2019) -
Growth Hormone Stimulation Testing Patterns Contribute to Gender Disparities in Growth Hormone Treatment
por: Kamoun, Camilia, et al.
Publicado: (2021) -
Racial/Ethnic Disparities in the Investigation and Treatment of Pediatric Growth Hormone Deficiency
por: Hawkes, Colin Patrick, et al.
Publicado: (2021) -
Treatment of Pre-pubertal Patients with Growth Hormone Deficiency: Patterns in Growth Hormone Dosage and Insulin-like Growth Factor-I Z-scores
por: Oberle, Megan, et al.
Publicado: (2017)